Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes

被引：0
|
作者：
Ilaria Cavallari
Alessia Delli Veneri
Ernesto Maddaloni
Rosetta Melfi
Giuseppe Patti
Nicola Napoli
Paolo Pozzilli
Germano Di Sciascio
机构：
[1] Campus Bio-Medico University of Rome,Department of Cardiovascular Science
[2] Campus Bio-Medico University,Department of Medicine, Unit of Endocrinology and Diabetes
来源：
Current Diabetes Reports | 2018年 / 18卷
关键词：
Diabetes; Lipid-lowering interventions; Cardiovascular disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies
    Tsushima, Takahiro
    Tsushima, Yumiko
    Sullivan, Claire
    Hatipoglu, Betul
    [J]. ENDOCRINE PRACTICE, 2023, 29 (06) : 491 - 497
  • [22] Lipid-lowering medications and risk of malignant melanoma: a Mendelian randomization study
    Yang, BoWen
    Wang, HanYu
    Song, WenYuan
    Feng, JiuHuan
    Hou, ShuFang
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [23] Lipid-lowering trials in diabetes
    Armitage, J
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 1999, 1 (0M) : M13 - M17
  • [24] Lipid-lowering in diabetes: An update
    Chait, Alan
    Eckel, Robert H.
    Vrablik, Michal
    Zambon, Alberto
    [J]. ATHEROSCLEROSIS, 2024, 394
  • [25] Lipid-lowering trials in diabetes
    Betteridge, DJ
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2001, 12 (06) : 619 - 623
  • [26] Do lipid-lowering medications prevent melanoma?
    Schilling, L
    Dellavalle, R
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 539 - 539
  • [27] Reasons for Discontinuation of Lipid-Lowering Medications in Patients with Chronic Kidney Disease
    Morrison, Fritha J. R.
    Zhang, Huabing
    Skentzos, Stephen
    Shubina, Maria
    Bentley-Lewis, Rhonda
    Turchin, Alexander
    [J]. CARDIORENAL MEDICINE, 2014, 4 (3-4) : 225 - 233
  • [28] Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease
    Delabays, Benoit
    de La Harpe, Roxane
    Vollenweider, Peter
    Fournier, Stephane
    Muller, Olivier
    Strambo, Davide
    Graham, Ian
    Visseren, Frank L. J.
    Nanchen, David
    Marques-Vidal, Pedro
    Vaucher, Julien
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (17) : 1856 - 1864
  • [29] Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease
    Knowles, Joshua W.
    Howard, William B.
    Karayan, Lala
    Baum, Seth J.
    Wilemon, Katherine A.
    Ballantyne, Christie M.
    Myers, Kelly D.
    [J]. CIRCULATION, 2017, 135 (22) : 2204 - 2206
  • [30] Atherosclerotic cardiovascular risk and simulation of lipid-lowering therapy in China
    Bi, L. E. I.
    Yi, J. Y.
    Wu, C. Q.
    Lu, J. P.
    Zhang, H. B.
    Yang, Y. A. N. G.
    Li, X. I.
    Zheng, X. I. N.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2567 - 2567
12345